See more : SNT Corporation (6319.T) Income Statement Analysis – Financial Results
Complete financial analysis of Zhaoke Ophthalmology Limited (6622.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhaoke Ophthalmology Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Corazon Mining Ltd (CZN.AX) Income Statement Analysis – Financial Results
- Muscat Capital – Al Masha’ar REIT Fund (4337.SR) Income Statement Analysis – Financial Results
- Amincor, Inc. (AMNCB) Income Statement Analysis – Financial Results
- Saniona AB (publ) (SANION.ST) Income Statement Analysis – Financial Results
- Bank of China Limited (BACHY) Income Statement Analysis – Financial Results
Zhaoke Ophthalmology Limited (6622.HK)
About Zhaoke Ophthalmology Limited
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 18.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 14.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 75.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 333.05M | 296.43M | 220.06M | 81.78M | 93.41M | 34.79M |
| General & Administrative | 23.15M | 18.14M | 48.71M | 15.29M | 2.05M | 1.15M |
| Selling & Marketing | 20.01M | 29.95M | 16.74M | 1.54M | 0.00 | 0.00 |
| SG&A | 43.16M | 48.09M | 65.45M | 16.84M | 2.05M | 1.15M |
| Other Expenses | 14.60M | 60.49M | 94.79M | 19.44M | 4.21M | 0.00 |
| Operating Expenses | 390.81M | 405.01M | 380.30M | 118.06M | 99.67M | 35.57M |
| Cost & Expenses | 395.32M | 405.01M | 380.30M | 118.06M | 99.67M | 35.57M |
| Interest Income | 77.40M | 30.42M | 5.04M | 2.58M | 2.89M | 1.31M |
| Interest Expense | 7.92M | 3.14M | 1.95M | 1.66M | 1.58M | 0.00 |
| Depreciation & Amortization | 48.70M | 35.07M | 25.83M | 19.85M | 16.57M | 7.03M |
| EBITDA | -327.86M | -369.10M | -377.53M | -100.70M | -86.47M | -28.91M |
| EBITDA Ratio | -1,748.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -376.57M | -404.18M | -364.33M | -725.33M | -120.49M | -35.94M |
| Operating Income Ratio | -2,008.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.92M | -3.14M | -1.77B | -1.66M | -22.36M | -940.00K |
| Income Before Tax | -384.49M | -407.32M | -2.13B | -726.98M | -122.08M | -36.88M |
| Income Before Tax Ratio | -2,050.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 550.00K | 3.14M | 4.44M | 1.66M | 1.58M | 0.00 |
| Net Income | -385.04M | -410.46M | -2.13B | -728.64M | -123.66M | -36.88M |
| Net Income Ratio | -2,053.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.71 | -0.76 | -5.18 | -1.36 | -0.23 | -0.23 |
| EPS Diluted | -0.71 | -0.76 | -5.18 | -1.36 | -0.23 | -0.23 |
| Weighted Avg Shares Out | 542.31M | 542.17M | 412.38M | 535.16M | 535.16M | 160.00M |
| Weighted Avg Shares Out (Dil) | 543.92M | 542.17M | 412.38M | 535.16M | 535.16M | 160.00M |
Source: https://incomestatements.info
Category: Stock Reports